ATNM Quote, Financials, Valuation and Earnings

MetaVia has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of --. Actinium Pharmaceuticals's return on equity of -95.08% beat MetaVia's return on equity of --.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 214.47%. On the other hand MetaVia has an analysts' consensus of $14.33 which suggests that it could grow by 2027.55%. Given that MetaVia has higher upside potential than Actinium Pharmaceuticals, analysts believe MetaVia is more attractive than Actinium Pharmaceuticals.

Actinium Pharmaceuticals has a beta of -0.325, which suggesting that the stock is 132.486% less volatile than S&P 500. In comparison MetaVia has a beta of 0.214, suggesting its less volatile than the S&P 500 by 78.621%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are larger than MetaVia quarterly revenues of --. Actinium Pharmaceuticals's net income of -$15.9M is lower than MetaVia's net income of -$3.7M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of -49.65%. Actinium Pharmaceuticals's return on equity of -95.08% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 214.47%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Actinium Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Actinium Pharmaceuticals has a beta of -0.325, which suggesting that the stock is 132.486% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Actinium Pharmaceuticals's net income of -$15.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 21.63%. Actinium Pharmaceuticals's return on equity of -95.08% beat Pfizer's return on equity of 8.72%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 214.47%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Actinium Pharmaceuticals has higher upside potential than Pfizer, analysts believe Actinium Pharmaceuticals is more attractive than Pfizer.

Actinium Pharmaceuticals has a beta of -0.325, which suggesting that the stock is 132.486% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Pfizer quarterly revenues of $13.7B. Actinium Pharmaceuticals's net income of -$15.9M is lower than Pfizer's net income of $3B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Tivic Health Systems has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of -2145.71%. Actinium Pharmaceuticals's return on equity of -95.08% beat Tivic Health Systems's return on equity of -192.41%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 214.47%. On the other hand Tivic Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that Actinium Pharmaceuticals has higher upside potential than Tivic Health Systems, analysts believe Actinium Pharmaceuticals is more attractive than Tivic Health Systems.

Actinium Pharmaceuticals has a beta of -0.325, which suggesting that the stock is 132.486% less volatile than S&P 500. In comparison Tivic Health Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Tivic Health Systems pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are larger than Tivic Health Systems quarterly revenues of $70K. Actinium Pharmaceuticals's net income of -$15.9M is lower than Tivic Health Systems's net income of -$1.5M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Tivic Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 3.35x for Tivic Health Systems. Usually stocks with elevated PS ratios are considered overvalued.